SUMMARY Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man. A prolongation in antipyrine half-life (Ti) was found in patients with liver disease, patients with chronic liver disease showing a greater increase than those with acute, reversible pathology. The most marked prolongation in TI was found in association with hypoalbuminaemia and hypoprothrombinaemia, suggesting that the cause for these changes was defective protein synthesis of microsomal enzyme protein. This hypothesis was suppoited by demonstrating that enzyme-inducing agents, which are known to increase the amount of microsomal enzyme protein, reduced the antipyrine half-life.
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As the liver is the major site for drug metabolism, patients with liver disease might be expected to show a defect in the elimination of drugs which are metabolized by the liver. In spite of traditional teaching to this effect (Sherlock, 1968; Fingl and Woodbury, 1970) , most studies have failed to show a consistent relationship between liver disease and altered drug disposition. Salicylic acid, aminopyrine, dicoumerol, antipyrine (Brodie, Bums, and Weiner, 1959) , tolbutamide (Nelson, 1964) , and phenylbutazone (Weiner, Chenkin, and Bums, 1954) have been shown to have a normal half-life (TO) in patients with liver disease, while some patients with liver disease have been shown to have a prolonged TI of carbenicillin (Hoffman, Cestero, and Bullock, 1970) , chloramphenicol (Kunin, Glazko, and Finland, 1959) , rifamycin (Acocella, Bonollo, Garimoldi, Mainardi, Tenconi, and Nicolis, 1972) , and amylobarbitone (Mawer, Miller, and Turnberg, 1972) . In a larger study, patients with liver disease who were receiving drugs known to induce drugmetabolizing enzymes (such as phenobarbitone) had a normal TI of phenylbutazone while patients not receiving inducing agents had a prolonged TI (Levi, Sherlock, and Walker, 1968) .
In the majority of the previous studies the number of patients investigated was small and when a prolongation of the TI was demonstrated, the correlation with the underlying disease process was poor. In an attempt to predict which patients with Received for publication 19 April 1973 liver disease would be likely to have abnormalities of drug metabolism, antipyrine was chosen as a model drug since it is completely absorbed when given orally, is almost entirely metabolized by the liver (Brodie and Axelrod, 1950) , is not toxic, and has the additional advantage of not being protein bound so that changes in plasma proteins as a result of liver disease should not alter its disposition. The effect of liver disease on its T4 has been measured and correlated with the clinical and biochemical parameters of hepatocellular function.
Methods

SUBJECTS
Fourteen normal drug-free subjects (aged 20-48) were studied as a control group. Eight subjects were studied on more than one occasion to assess day-today variation.
The As there is no evidence in previous publications of dose-dependent kinetics for antipyrine, a standard dose of 1200 mg antipyrine was administered orally after a fasting control blood sample was obtained. A further four or five blood samples (10 ml) were taken between two and a half and 24 hours after the drug had been given. The serum was separated and frozen until assayed in duplicate by the method of Brodie, Axelrod, Soberman, and Levy (1949) . From these data the TI was determined by regression analysis. When the fall in antipyrine concentration was less than 25% over 24 hours the TI could not be calculated accurately from a 24-hour sampling period, so that the arbitrary upper limit of 50 hours was imposed.
Following the determination of the antipyrine TI, 22 patients received phenobarbitone 30 mg tds for three days and the TI was determined again. 
Results
In control subjects ( fig 1) the TI of antipyrine was 12.0 ± 1.7 hours (SEM) (range 6-17 hours) which is consistent with previously published data (Brodie et al, 1959; Vesell and Page, 1969 The biochemical parameters measured in all patients with liver disease, except patients receiving enzyme-inducing agents (table II), showed that patients with a serum albumin below 3 g0% or a prothrombin index below 80%, in spite of parenteral vitamin K, had a prolonged antipyrine Ti. The TI of patients who had either of these abnormalities was significantly longer than the TI of the remaining patients with liver disease (fig 2) . Abnormalities of serum bilirubin, alkaline phosphatase, and aspartate transaminase did not correlate with the prolongation in antipyrine Ti.
The three-day course of phenobarbitone reduced the antipyrine TI from 30.3 ± 6-2 hours to 20.5 + 5.4 hours (paired t test P < 0.001). Prednisone was also found to shorten the TI in five patients with chronic active hepatitis to 13.8 ± 6.0 hours compared to that in untreated patients (38.3 ± 14.6 hours). This difference is unlikely to be due to clinical improvement following therapy as the clinical and biochemical parameters are similar in the two groups (table III) 86-0 ± 6-0 3-4 ± 0-27 11-2 ± 70 48-4 ± 19 1 48-6 + 3-8 Patients not receiving prednisone 38-3 + 14-61 1 0 1 78-4 ± 7-3 3-2 ± 0-24 9-2 ± 5-8 23-2 ± 7-2 190-8 i 108 retention. The rate of elimination of some drugs is dependent upon liver blood flow (Whitsett, Dayton, and McNay, 1971; Stenson, Constantino, and Harrison, 1971 ) and a reduction in total liver blood flow might be expected to increase drug Ti. Disturbed regional blood supply in liver disease might therefore have been an explanation for our results.
However, when the antipyrine Ti in patients with evidence of portosystemic shunts was compared with that in patients with similar liver pathology, but no evidence of a shunt, there was no difference; both were increased from normal. The evidence suggests that the impairment in antipyrine elimination is greatest when heptocellular function is severely compromised. A prolonged prothrombin time not responding to parenteral vitamin K and a low serum albumin are well established as features of failing function of the liver parenchyma, representing a failure of protein synthesis. Patients who had either of these abnormalities showed the greatest prolongation in Ti and had no overlap with the normal range. Other clinical and biochemical parameters failed to correlate with the antipyrine TI; this is probably because they are not always directly related to the metabolic function of the liver and may be influenced by many other factors.
The previous report of normal Ti of antipyrine in patients with liver disease (Brodie et al, 1959) might be explained by two factors. The first is that their study may not have included patients with hypoalbuminaemia or hypoprothrombinaemia. Secondly, these patients may have been receiving enzymeinducing agents, a factor which has been shown to obscure the prolongation of the Ti of phenylbutazone in patients with liver disease (Levi et al, 1968) . In the present series psychotropic, antihistaminic, and hypnotic drugs were actively avoided. Nitrazepam, previously shown not to cause enzyme induction (Bieger, de Jonge, and Loeliger, 1972) , was the only hypnotic drug used. The only patients receiving a recognized enzyme-inducing agent were those with chronic active hepatitis receiving prednisone; although small, this group was representative in its composition of patients with hepatocellular failure yet the mean antipyrine Ti was within the normal range. A short three-day course of phenobarbitone in low doses was also found capable of reducing the half-life significantly. Indeed, the increased Ti of antipyrine might have returned to normal if patients with liver disease had been treated with an optimal course of enzyme-inducing agent.
The results of this study suggest that the cause of the prolongation of the Ti of antipyrine in patients with liver disease might be defective synthesis of microsomal enzyme protein. First, the parameters of hepatocellular function associated with a marked prolongation of antipyrine Ti are related to impaired protein synthesis. Secondly, when phenobarbitone is given in small doses for a short time there was a reduction in half-life, and phenobarbitone is known to exert this effect through an increase in the absolute amount of microsomal enzyme (Conney, Davison, Gastel, and Burns, 1960) . It is interesting that when prednisone is given for a longer period the antipyrine Ti returned to normal, suggesting that impaired microsomal enzyme function can be significantly improved even in severe liver disease.
In conclusion, it is suggested that hepatic microsomal metabolism is generally impaired in liver disease. This impairment is greatest in patients with chronic disease and hypoprothrombinaemia or hypoalbuminaemia and can be reversed by the administration of enzyme inducing agents. 
